TP53 and lymphoma: Restoring Trp53 function in established Eμ-Myc lymphomas demonstrates the therapeutic potential for Trp53 restoration (253), which is analogous to the stabilization of Trp53 by treatment with Mdm2/Mdmx inhibitors.